Advertisement


Ghassan K. Abou-Alfa, MD, on HCC: Results From the CELESTIAL Trial

2018 Gastrointestinal Cancers Symposium

Advertisement

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings on cabozantinib vs placebo in patients with advanced hepatocellular carcinoma who have received prior treatment with sorafenib (Abstract 207).



Related Videos

Hepatobiliary Cancer
Immunotherapy

Andrew X. Zhu, MD, PhD, on HCC: Results From KEYNOTE-224

Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses study findings on pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (Abstract 209).

Pancreatic Cancer
Immunotherapy

Steven D. Leach, MD, on Pancreatic Cancer: Keynote Lecture

Steven D. Leach, MD, of Dartmouth University’s Norris Cotton Cancer Center, discusses the personalized approach that GI cancers will require to make rational use of immunotherapy—including a subset of pancreatic cancers, which appear to be highly immunogenic and are associated with long-term survival.

Gastrointestinal Cancer

Khaldoun Almhanna, MD, MPH, on Gastric Cancer: Results From the CCOG 1102 Trial

Khaldoun Almhanna, MD, MPH, of the H. Lee Moffitt Cancer Center, discusses the long-term outcome of a phase III study that explored the significance of extensive intraoperative peritoneal lavage in addition to standard treatment for ≥ T3 resectable gastric cancer (Abstract 1).

Gastroesophageal Cancer

Abraham J. Wu, MD, on Esophageal Cancer: Impact of Lung and Heart Dose on Survival After Radiotherapy

Abraham J. Wu, MD, of Memorial Sloan Kettering Cancer Center, discusses his findings that suggest efforts to reduce lung dose, such as shrinking the treatment volumes or using proton therapy, may improve outcomes in esophageal cancer (Abstract 3).

Pancreatic Cancer

Kyaw L. Aung, MBBS, PhD, on Pancreatic Cancer: Results From the COMPASS Trial

Kyaw L. Aung, MBBS, PhD, of Princess Margaret Cancer Centre, discusses early study findings on genomics-driven precision medicine for advanced pancreatic ductal carcinoma (Abstract 211).

Advertisement

Advertisement



Advertisement